At 9 mg, people without diabetes had 34.3 fewer breathing events per hour versus 9.9 on placebo, and lost up to 22.2% of body weight. The drug is still investigational.
Recap by typeshit. Full story at Daijiworld.
Half of people with diabetes for 10 years or more said they were very satisfied on a GLP-1. Gen Z users were the most likely to stop and restart treatment.
64% of current users faced some negative reaction. Men, BIPOC respondents and the newly diagnosed reported it most, while 69% of boomers felt none.
The workflow uses glutathione or sulfatase triggers to target organelles and tumors in mice, and the authors say it takes 92 to 115 days to run.
A University of Pennsylvania mouse study found on-off GLP-1 use left mice 20 per cent heavier than those kept on the drug, and doctors warn human effects are unknown.
The Frier Levitt partner warns that drugmakers have deep pockets to pursue sellers, and notes knockoffs of the unapproved drug are already circulating.
Nyah Phengsitthy reports Lilly is staking out a new battlefront around an unapproved obesity treatment. The full story has the details.
Loading…